Roche Diagnostics Corporation

Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostic equipment, reagents, laboratory instruments, and associated medical products, supplies clinical laboratory analyzers, molecular diagnostic systems, histology staining platforms, point-of-care testing devices, and specialized reagents to the Department of Veterans Affairs, Defense Health Agency, and other federal healthcare agencies as a prime contractor with no set-aside activity across its federal footprint.

Roche Diagnostics operates as a wholly owned subsidiary of Foundation Medicine, Inc., itself a foreign-owned for-profit organization. The vendor's federal work centers on NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing) and related analytical instrument manufacturing and repair categories, with primary PSC codes covering laboratory equipment and supplies, in vitro diagnostic substances and reagents, and medical-surgical instruments. Recent federal activity spans over 16,600 prime contract awards valued at $5.53 billion combined potential value across 133 distinct customer agencies, with obligated dollars reaching $2.15 billion (39% of combined potential). Activity has declined modestly year over year—341 awards in 2022 to 142 awards through October 2026 (a partial-year count)—reflecting maturation across multiple established contract vehicles rather than loss of customer base.

The vendor's customer concentration is heavily weighted toward the VA system and Department of Defense healthcare operations. The Department of Veterans Affairs (across all component VISNs and central directorates) accounts for a significant share of awards by count; the Defense Health Agency leads by dollar value at $391.4 million combined potential across 357 awards. The Department of Health and Human Services Centers for Disease Control and Prevention ranks second by potential value ($295 million across 405 awards). Top customers by award count include VA (614 awards, $2 million combined value—a data artifact suggesting older or small awards), Indian Health Service (539 awards, $68.1 million), Army Medical Command (479 awards, $215.6 million), Navy Bureau of Medicine and Surgery (466 awards, $94.8 million), and VA VISN 10 (426 awards, $154.6 million). The top five customers by potential value account for roughly 24% of the vendor's combined federal value, indicating moderate diversification across federal healthcare and research agencies.

Roche Diagnostics' federal work is predominantly delivered through GSA Schedule vehicles and indefinite delivery contracts. The Critical Analyzers, Laboratory (FSS-66-III) schedule supports 2,413 task orders worth $1.05 billion combined potential value—the single largest vehicle. Federal Supply Schedule V797P5472X (2,217 task orders, $156.1 million), the In Vitro Diagnostics, Reagents, Test schedule (954 task orders, $91.9 million), and additional GSA schedules (GS24F1283C with 694 task orders; V797P6571A with 641 task orders) provide secondary procurement channels. These vehicles allow federal agencies to access Roche's diagnostic products on pre-negotiated pricing without requiring individual competitive solicitations. Representative recent awards include a $1.685 million delivery order from the Defense Health Agency (October 1, 2026) for an automated core lab under firm fixed-price terms; a $181,539.67 delivery order from Veterans Integrated Service Network 2 (September 1, 2026) for a clinical laboratory immunohistochemistry stainer system under a CPRR (cost-per-reportable-result) pricing model with base plus four option years; a $5.37 million VISN 10 delivery order (March 19, 2026) for Roche Ventana reagents supplying the Cleveland VA Medical Center; and a $3.58 million VISN 19 call order (May 1, 2026) for chemistry testing services under the FSS-66-III schedule. Sole-source and single-award IDIQs are prevalent when Roche's equipment or reagents are the only compatible option for existing federal systems—for example, a January 25, 2026 IDIQ with VISN 4 (ceiling $1.896 million) for immunohistology laboratory services justified as necessary to support existing Roche-owned analyzers, and an April 21, 2026 IDIQ with VISN 17 (ceiling $1.4 million) for Ventana-exclusive reagents and consumables following a sole-source special notice.

Recompete exposure in the next twenty-four months totals 253 awards with combined potential value of $153.1 million—a moderate refresh requirement that will test Roche's competitive position, particularly on base-period expiring GSA schedules and VA network-specific vehicles. The vendor executes nearly all federal work as prime contractor (100% of the portfolio by count); sub-award activity is minimal (10 sub-awards total, representing suppliers to Battelle Memorial Institute and Cardinal Health). SCI-reportable invoicing of federal service contracts is negligible ($82 thousand across FY2023 only, with 0.1 FTEs)—the source reflects goods and product procurement rather than labor-intensive service delivery. Government-paid rates on the minimal SCI-reportable service work average $380.35/hr, consistent with technical diagnostic services.

Roche Diagnostics competes full-and-open across its federal footprint with no utilization of small-business set-asides, indicating competition against the broadest vendor pool and positioning as a full-capability, established federal supplier. The vendor's federal strategy centers on depth within VA and DoD healthcare ecosystems, leveraging GSA Schedule incumbency to sustain delivery orders across multiple VISNs and military medical facilities, combined with single-source or sole-source IDIQs that tie federal customers to Roche when equipment or reagent compatibility is the controlling procurement factor.